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Purpose:This prospective study was designed to assess the technical success and outcome after patients with thoracic aortic
pathology at high risk for conventional therapy were treated with the Zenith TX1 and TX2 endovascular graft.
Methods: Between 2001 and 2004, patients at high risk for conventional surgical therapy presenting with chronic aortic
dissections, thoracic aneurysms, or aortobronchial or aortoesophageal fistulas were treated with a single- or multiple-
piece endovascular grafts. Surgical modification of proximal or distal fixation sites was performed when necessary to
establish adequate regions for device landing zones. Follow-up studies included radiographic evaluation before discharge
and at 1, 6, 12, and 24 months. Aortic morphologic characteristics were determined by using three-dimensional imaging
studies and centerline of flow measurements. Statistical analyses were performed with Kaplan Meier analysis to assess
survival, factors predictive of poor outcome, and morphologic changes, including sac shrinkage.
Results: A total of 100 patients (42% women) were treated, including 81 aneurysms, 15 aortic dissections (with
aneurysms), 2 patients with fistulous connections (1 aortobronchial and 1 aortoesophageal), 1 subclavian artery
aneurysm, and 1 aortic rupture. Mean follow-up and aneurysm size were 14 months and 62 mm, respectively. Most
patients (55%) had undergone prior aortic aneurysm repair. Surgical modifications were required to create adequate
implantation sites in 29% patients, including 14 elephant trunk/arch reconstructions, 18 carotid-subclavian bypasses,
and 4 visceral vessel bypasses. Iliac conduits were required in 19 patients. Overall mortality was 17%, and aneurysm-
related mortality was 14% at 1 year. Sac regression (>5 mm maximum diameter decrease) was observed in 52% and 56%
at 12 and 24 months. Growth was noted in one patient (1.6%) at 12 months. Endoleaks were detected in eight patients
(8.5%) at 30 days and three patients (6%) at 12 months. Secondary interventions were required in 15 patients. Migration
(>10 mm) of the proximal or distal stent was noted in three patients (6%) (two proximal and one distal), none of which
required treatment or resulted in an adverse event.
Conclusions: Acceptable intermediate-term outcomes have been achieved in the treatment of high-risk patients in the
setting of both favorable and challenging anatomic situations with these devices. The complexity of the patient
population, in contrast to endovascular infrarenal repair, attests to the differences in the pathophysiology aortic disease
in the anatomic beds. (J Vasc Surg 2005;41:589-96.)Endovascular thoracic aortic aneurysm repair is a natu-
ral progression of technology initially introduced in
19911,2 for aneurysm repair. Several reports of early expe-
riences with homemade and commercially manufactured
devices have been authored.3-5 Indications for endovascu-
lar treatment of thoracic pathology have included aortic
diverticulum, aneurysms, acute dissections, chronic dissec-
tions, and aortobronchial fistulae. However, the guidelines
for repair of thoracic diseases are less defined than infrarenal
aneurysms.
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doi:10.1016/j.jvs.2005.01.043Problems similar to those encountered with infrarenal
endovascular grafts, including endoleak, migration, rup-
ture, and an increased need for secondary interventions,
also plague the thoracic endovascular procedures, and de-
vice stability and integrity may be more hampered by the
inherently challenging anatomy and relatively greater he-
modynamic forces within the aorta. The Zenith thoracic
device (Cook, Blooomington, In) described in this report
originated from an international collaborative effort. The
most recent version of this device is undergoing a United
States phase II multicenter trial and is commercially avail-
able in Europe, Australia, and Canada.
METHODS
This study was performed under the guidance of a
sponsored investigational device exemption that began in
February 2001, with prospective data collection continuing
through April 2004. All patients enrolled were considered
to be at high risk for a conventional surgical repair, had
agreed to participate in the study, and signed an informed
consent form approved by the institutional review board.
Inclusion criteria are listed in Table I.
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less steel Z-stents (Terumo-Vascutek Inc, Glasgow, Scot-
land) attached to a conventional thickness polyester fabric
with ethibond sutures in an attempt to minimize intercom-
ponent movements. Two primary device options were
available throughout the study (Fig 1).
The proximal fixation system for both TX1 and TX2
devices consists of an internal Gianturco Z-stent with a
series of 5-mm long barbs caudally oriented that extend
through the polyethylene terephthalate fabric in a stag-
gered configuration. The distal fixation system employs an
uncovered Gianturco Z-stent with 5-mm barbs staggered
and cranially oriented. The diameters available were 22mm
to 42 mm in 2-mm increments, and the lengths were 77
mm to 220 mm.
The delivery system incorporated a means to afix the
proximal and distal portions of the endografts to a central
core (Fig 2). Thus, deployment of the entire segment of the
covered stents without the induction of hypotension or
bradycardia was possible, while to a certain extent, elimi-
nating any rushed deployment and preserving the ability to
reposition the device during the deployment process. A
20F system was used for devices34 mm in diameter, and
a 22F system was required for the rest of the devices.
The delivery system underwent several changes during
the course of the study, including the addition of a pre-
curved proximal portion to assist with manipulation
through the aortic arch and alterations to the trigger wire
systems (the mechanism used to attach the device to the
delivery system). The later change involved conversion of
the trigger wires from a stainless steel design, where tortu-
Table 1. Inclusions criteria for patient enrollment
Inclusion criteria
Pathology Thoracic aneurysm 5cm or anuerysm
with a history of rapid growth
Subclavian aneurysm 2.5cm
Chronic aortic dissection with
aneurysm 5 cm or rapid growth
Comorbidities Life expectancy 2 years
High-risk for open surgical repair*
Absence of an uncorrectable
coagulopathy
Absence of allergy to stainless steel or
polyester
Absence of a serious groin infection
Absence of systemic sepsis
Anatomic
Proximal and distal
necks
Length 10mm
Diameter 40 mm
Access Iliac arteries 7mm in diameter†
Absence of severe angulation†
*This was a relatively subjective assessment of comorbid conditions includ-
ing cardiac, pulmonary, renal, prior surgical procedures, and anatomic
complexity. In general, patients were seen by a cardiothoracic surgeon as
well as a vascular surgeon prior to repair to determine open surgical risk.
†The use of an iliac conduit was acceptable to treat patients with iliac disease
that did not meet the stated inclusion/exclusion criteria.ous cases caused some kinking, to a series of nitinol wires.In addition, the proximal trigger wire was supplemented
with two additional wires, making a triad of wires to prop-
erly constrain and stabilize the device during deployment.
A further change, intended to remove any possibility of
sheath kinking, was changing the sheath material from a
standard expanded polytetrafluoroethylene (PTFE) design
to a braided sheath.
Preoperative imaging information was obtained from
high-resolution spiral computed tomography CT) scans
evaluated using three-dimensional (3D) technology (Sei-
mens Leonardo Workstation and TeraRecon 3D software
programs). Aortic diameters were computed at the desired
proximal and distal fixation sites. Lengths were calculated
using centerline of flow algorithms, unless in straight seg-
ments. Angiography was used selectively.
Oversizing ranged from 10% to 25%, and graft lengths
were intended to extend 3 cm (if possible) into the normal
aorta proximal and distal to the offending pathology. Mod-
ular devices were designed to have an extensive degree of
overlap (5 cm). In this setting, the proximal component
was designed to terminate at the distal end of the aneurysm
or immediately proximal to any significant aortic tortuosity.
The distal component then extended from the proximal
portion of the aneurysm through the distal sealing zone.
Implantation procedure. Procedures were per-
formed in an endovascular operating room with a fixed
imaging system (Siemens Angiostar or Axiom Artis FA).
General, regional, or local anesthesia was used at the dis-
cretion of the anesthesiologist, patient, and surgeon. Spinal
drains were used selectively when the perceived risk of
paraplegia was high, and when inserted, to administer
regional anesthetics. Femoral access was established after
arterial exposure with an oblique incision in conjunction
with a counter incision. A second access site was used in all
patients and included the left brachial artery for some
proximal aneurysms, the right brachial artery in the setting
of elephant trunk completion procedures, and the con-
tralateral femoral in the setting of most thoracic lesions.
Patients received heparin anticoagulation.
Endovascular grafts were inserted over a stiff wire (Lun-
derquist or Amplatz Wire, Cook, Inc), and deployed with-
out specific manipulation of the blood pressure or heart
rate. A balloon was selectively used to achieve appropriate
device conformity at the sealing locations. Completion
angiography was performed using a rapid frame rate (6 to
7.5 frames per second) to differentiate cardiac motion from
contrast extravasation.
Follow-up. The follow-up protocol required patients
to undergo CT scanning and chest radiography before
discharge, at 30 days, and at 6, 12, and annually thereafter.
Physical examinations, basic laboratory studies, and ankle
brachial indices were also obtained at the follow-up visits.
Image analysis was conducted on work stations. Morpho-
logic changes are reported in adherence to the reporting
standards for endovasuclar aneurysm repair.
Data definitions and statistical analysis. Technical
success was defined as placement of a patent endoprosthesis
in the desired location in the absence of a type I or III
a TX
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eurysm size, endoleaks, mortality, and other descriptive
characteristics are reported in compliance with the most
recent endovascular aneurysm repair reporting standards
document.6
RESULTS
A total of 100 patients were treated (97 based on the
investigational device excemption inclusion criteria and 3
on a compassionate-use basis), with a mean age of 69 years
(range, 37 to 86). The breakdown of etiology of aortic
pathology and type of device used are summarized in Table
2. Mortality, diameter changes, and migration are catego-
rized by pathology and listed in Table 3 and Fig 3. Ob-
served endoleaks are categorized in Fig 4.
Technical success was achieved in 87.6% patients who
Fig 1. The implant components of Zenith TX1 and T
systems on a single component. B, The TX2 fixation sy
component, with an intended minimum of a two-stent o
barbs on the TX1 device and the proximal component of
TX2 system has no distal barbs and terminates distally in a
has a two-stent overlap zone where the stents are sutur
material (yellow arrow). Distally, this piece has an uncover
to prevent proximal migration of the distal sealing stent.
pathology, whereas more diffuse disease was treated withmet the study inclusion criteria and in all patients treated ona compassionate-use basis. Aneurysm-related death oc-
curred in 13 patients (7 30 days of the procedure, 3
deaths were attributed to the aneurysm but yet were unre-
lated to the acute procedure). Three patients died from
unrelated causes (see Table IV).
Neurologic complications. Spinal cord ischemia was
suspected in six patients, and complete and permanent
paraplegia developed in two. One case of paraplegia was
attributed to distal embolization that resulted in multisys-
tem organ, and the patient ultimately died. The other
paraplegic patient had extensive aortic coverage (midarch
after a carotid subclavian bypass up to the celiac artery) in
the setting of a single hypogastric artery.
Three cases of paraperesis were noted, two of which
were asymmetric (involving only one leg). All paraperetic
patients recovered substantially before hospital discharge.
stems. A, The TX1 has the proximal and distal fixation
is split between a proximal (TX2P) and distal (TX2D)
p between them. Note the presence of caudally oriented
X2 system (red arrows). The proximal component of the
rnally mounted sealing stent. The distal TX2 component
the internal portion of the polyethylene terephthalate
nt with cranially oriented barbs (white arrow) in an effort
amentally, the TX1 device was used to treat focal aortic
2 device.X2 sy
stem
verla
the T
n inte
ed to
ed ste
FundA single case of late paraperesis occurred 1 year after device
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April 2005592 Greenberg et alFig 2. The delivery system consists of (A) a tapered tip with a gradiant stiffness that may be precurved to fit into the aortic
arch, a polytetrafluoroethylene sheath, and a handle. Three nitinol wires attach the proximal component to the delivery
system. A single wire, in conjunction with the bottom cap (which constrains the distal uncovered stents with crainially
oriented barbs), attaches the distal portion of the device (B and C, respectively). The delivery system for the proximal piece
of the TX2 has only one trigger wire. D, After exposure of the prosthesis by sheath withdrawal, the single trigger wire is
released (red arrow) allowing expansion of the proximal stent and barbs. E, The TX1 delivery system and distal component
of the TX2 delivery system contain trigger wires for both the proximal and distal barbed regions (red arrows).
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fracture with presumed hypotension. The definitive associ-
ation of the latter four cases with a spinal perfusion defect
remains in question.
Cerebral ischemic/embolic infarcts occurred in three
patients, all of whom had aneurysms of the arch or proximal
descending thoracic aorta. Despite the absence of detect-
able embolic events on cerebral angiography in two of the
three cases (the last did not undergo a cerebral angiogram),
the CT scans all demonstrated embolic patterns. Two
strokes occurred acutely during the procedure in the ab-
sence of a general anesthetic and occurred at the time of
balloon inflation within the aortic arch.
Secondary procedures. Fourteen patients underwent
secondary procedures. The recurrance of an aortobronchial
fistula required coverage of more proximal aorta 1 year after
the initial prosthesis was placed for an initial aortobronchial
fistula. To treat this patient, a carotid-carotid-subclavian
bypass was performed, and an expanded PTFE prosthesis
(W.L.Gore, Flagstaff, Ariz) was placed with the intention of
improving the microbial resistance characteristics. The pa-
tient has done well through 3 years of follow-up and
remains on oral antibiotics.
Two proximal type I endoleaks were treated with prox-
imal extensions. A further proximal type I endoleak was
treated with a fenestrated extension incorporating the left
common carotid artery origin. One distal type I endoleak
was treated with a distal fenestrated extension graft incor-
porating the celiac and superior mesenteric arteries. A
persistent type II endoleak from retrograde flow via the left
Table II. Demographic and procedural information
Thoracic
aneurysm
Chronic dissection
with aneurysm Other*
Number of patients 81 15 4
Age (years) 71 54 71
Male sex 56% 73% 50%
Prior aortic repair 58% 27% 75%
Mean aneurysm size(mm) 64 55 68
Surgical modification 40% 0% 75%
Proximal neck 35% 0% 50%
Distal neck 5% 0% 0%
Conduit 24% 0% 0%
TX1 device 56% 67% 100%
TX2 device 44% 33% 0%
Operative time (min) 143 102 138
General anesthesia 12% 0% 50%
Regional anesthesia 88% 100% 50%
Fluoroscopy time (min) 18 15 13
Contrast dose (mL) 135 121 107
Estimated blood loss (mL) 490 168 500
Spinal drain 85% 82% 75%
Acute spinal cord ischemia 7.4%† 6 (2) 0% 0%
Acute CVA 2.5% 0% 25%
CVA, Cerebrovascular accident.
*Includes 1 subclavian aneurysm, 1 aortobronchial fistula, 1 aortoesopha-
geal fistula, and 1 thoracic rupture.
†Expressed as the total number of cases including temporary paraperesis.
Peremanent paralysis numbers are deonted within the parentheses.subclavian artery was treated with glue embolization. Asingle type III endoleak at the modular joint of a TX2
device within a calcified aorta was treated with the place-
ment of a large Palmaz stent (Cordis Endovascular, Great
Lakes, NJ). All of these endoleaks resolved after the sec-
ondary procedure.
After 1 year of observation, an endoleak of unknown
origin that occurred after the completion of an elephant
trunk procedure was treated with proximal and middle
graft extension pieces. The endoleak persists at the 2-year
and 3-year follow up visits. It is visible only at the aneurysm
margins on the delayed contrast CT images and has been
considered a type II endoleak. The aneurysm sac size has
remained stable.
Low-grade mesenteric ischemia developed in one pa-
tient after a four-vessel mesenteric bypass and total thora-
coabdominal aortic coverage. The ischemia likely resulted
from a compressed limb of the distal bifurcated device
ipsilateral to the inflow to the gut. The patient was treated
with the placement of a Palmaz stent (Corids Endovascu-
lar) within the kinked limb, which resolved the problem.
Two years after treatment of a proximal chronic dissec-
tion in an additional patient, the aortic segment distal to the
endovascular repair demonstrated continued growth. He
underwent open repair in which the distal aspect of the
stentgraft was used to construct the proximal anastomosis
of the thoracoabdominal repair.
Five additional secondary procedures were performed
for complications resulting from the stent-graft surgery,
including 3 common femoral access site issues, 1 brachial
artery thromboses, and one groin hematoma evacuation.
Most patients had diminishing aneurysm size 12
months. Only one patient was noted to have increasing
aneurysm size. This occurred in the setting of a proximal
type I endoleak that was treated with a secondary procedure
after the 1-year follow-up visit.
DISCUSSION
Ideally, a thoracic endovascular graft will be flexible
enough to accommodate the requisit tortuosity of the arch,
incorporate a fixation system that is secure both proximally
and distally, seal within both straight and tortuous seg-
ments, be readily deliverable, and have favorable effects on
the excluded region of the aorta. Additionally, delivery of
the device would optimally not require the induction of
hypotension or bradycardia and should be easily accom-
plished despite the proximity of pathology to the aortic
valve in the setting of extreme tortuousity.
Unfortunately, such an optimal design does not yet
exist. Specific problems that have been reported with the
use of predicate designs included migration of both the
proximal and distal fixation systems,3 erosion of uncovered
proximal stents through the aortic arch,7 and component
separation when modular thoracic grafts were used.3,5 Sim-
ilar problems have been described after implantation with
other prostheses.5,8,9 The devices described in this report
has been designed to specifically address some of these
concerns.
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intended to discourage distal migration of this stent in a
manner similar to the Zenith abdominal aortic aneurysm
device. The crainially oriented barbs on the distal stent are
intended to prevent proximal migration of the distal stent
and allow for accurate delivery in the region of the visceral
vessels. Increased overlap within the two-piece design has
been encouraged to minimize the risk of component sepa-
ration and provide a degree of flexibility during the device
deployment to allow for procedure-related alteration of
aortic length (straightening of tortuous segments). Fur-
thermore, the staged deployment of the proximal and distal
fixation systems allows one to concentrate solely on how
close the graft material is to the aortic branches without
regard to the rest of the aorta.
Two thoracic devices are currently undergoing studies
in the United States, and one was recently approved for use
in thoracic aneurysms (TAG,W.L. Gore&Assoc, Flagstaff,
Ariz), while all are commercially available in Europe and
Table III. Results of treatment classified in terms of prese
Overall
No. patients 100
Survival 30 days 93%
12 mon 83%
24 mon 77%
Secondary pocedures Overall (mon) 15
Sac shrinkage 12 (n  48) 52%
24 (n  24) 56%
Sac growth 12 1.6%
Migration 12 6.0%
*Survival numbers are calculated using Kaplan-Meier analyses. Sac shri
postprocedure film establishing the baseline size, and a change in diamete
movement and is based on centerline of flow measurement calculations from
†Includes 1 subclavian artery aneurysm, 1 aortobronchial fistula, 1 aortoeso
‡In each category, group A refers to patients who were primarily treated w
visceral vessel bypass to create an adequate proximal or distal landing site.
Fig 3. Kaplan-Meier analysis of mortality. Results are expressed
in terms of all cause mortality and thoracic aneurysm repair related
mortality. TAA, thoracic aortic aneurysm.Australia including the Zenith, TAG and Talent devices(Medtronic AVE, Minneapolis, Minn). Although each de-
vice has merits, each has its faults.
The device described here requires the use of relatively
long (17 to 22 mm) proximal and distal sealing stents. This
precludes optimal flexibility and complicates sealing within
tortuous segments such as the aortic arch. To overcome
this, the sealing stent must be placed into a relatively
straight aortic segment.
The delivery system resembles the Zenith abdominal
device in that it handles tortuous iliac arteries nicely, but the
sheath can kink in the setting of extreme arch angulation,
making graft deployment difficult. This did not prevent
treatment of any patients in this series and was later cor-
rected with a new delivery system that incorporates braided
technology and is markedly more flexible.
The desire to treat several types of thoracic pathology
has outpaced the development or validation of devices used
pathology*
Thoracic aneurysms
Chronic dissections
with aneurysm
Other†A‡ B‡ A‡
64 17 15 4
2% 100% 100% 50%
1% 81% 100% 50%
6% 70% 100% 50%
7 5 2 1
4% 38% 55% 50%
8% 50% 55% 50%
2.3% 0% 0% 0%
6.3% 0% 11% 0%
is based upon three-dimensional imaging analysis with the immediate
g defined as 5 mm in either direction. Migration is defined as 10 mm
er the left common carotid artery or celiac artery.
al fistula, and 1 thoracic aortic rupture.
endovascular graft. Group B patients required either an elephant trunk or
Fig 4. Type of endoleak and temporal incidence of endoleak for
the combined experience (all pathologies, all device types).nting
9
8
7
5
5
nkage
r bein
eith
phage
ith anfor unintended diseases. The obvious example is the use of
s pos
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ities exist in the location of the device placement in many
circumstances, the treatment goals are entirely different,
and the forces endoprostheses encounter after implantation
are drastically diverse. For these reasons, we did not include
any patients treated for acute aortic dissections and limited
the use of this device to chronic dissections in the setting of
aneurysms 5 cm in addition to patients with more tradi-
tional aneurysms. When treating the chronic dissections,
we attempted to seal above and below the dissected lumen
when possible, and extra-anatomic bypass procedures were
frequently required. Overall, the series represents a rela-
tively complex population where a little more than half of
the patients had undergone aortic procedures before treat-
ment with this endovascular graft.
Spinal cord ischemia has long been heralded as the
Achilles heel of thoracic and thoracoabdominal aortic re-
pair. The incidence of spinal cord ischemia in this series is
not dissimilar to prior reports.3,5,9,10 Although two cases of
paraplegia were noted, only one was attributed to a pure
intercostal coverage affect. Spinal cord drainage was used
preoperatively in the setting of extensive aneurysms and in
all patients with a prior aortic repair or with compromised
hypogastric circulations. In addition, drainage was insti-
tuted in all patients with a postprocedure deficit, where the
perfusion pressure was presumably increased by lowering
the drain to 5 cm H2O. This technique was applied more
liberally earlier in our experience andmore selectively in the
later years. No adverse events were attributed to the spinal
Table IV. All mortalities potentially associated with the p
Categorization Cause of death POD
30 days
MI 17 Out
MI 18 In h
MSOF 15 Isch
of
MSOF 10 Dist
Pneumonia 28 Suffe
re
AAA rupture 14 Kno
AEF* 1 Com
un
31-365 days
MSOF 40 Dist
Pneumonia 93 Reco
fa
Sepsis 185 Dev
pr
af
Pneumonia† 215 Ven
de
365 days
MI 366 Suffe
Aortobronchial fistula 451 End
no
th
POD, Postoperative day;MI,myocardial infarction;MSOF,multisystem orga
aortoesophageal fistula.
*An autopsy performed demonstrated the stent graft was in good position.
†Preprocedure ventilator dependency with resultant pneumonia 6 month
procedure.drainage catheters.Strokes were uncommon. Two of the three events in
this series occurred acutely during balloon inflation within
the arch. Consequently, we are now reluctant to use a
balloon in this region, and do so only in the setting of
proximal endoleak or misaligned device.
The behavior of the device and aneurysm sac is critical
to chart during the follow-up studies. However, unlike the
abdominal aorta where severe tortuousity is a relative con-
traindication for repair, the thoracic aorta is inherently
tortuous. Therefore, measurements pertaining to aneurysm
size and device migration clearly must be peformed using
3D imaging and centerline of flow techniques. Aneurysm
shrinkage was present in most patients, providing assurance
that the natural history of the aortic disease is reversed.
Despite the belief that significant morphologic changes
may be associated with component separation,11,12 no
component separations were observed in this series. Migra-
tionmay occur as a result of loss of fixation system integrity,
progression of aortic disease in terms of dilatation of fixa-
tion sites, or simply after continued exposure to the ex-
treme hemodynamic forces present in the thoracic aorta.
The crainially oriented distal barbs and caudal proximal
barbs are intended to discourage migration.
Reporting standards have not been published defining
migration for thoracic endoprostheses. Ultimately, the goal
must be to have no migration; however, given the likeli-
hood of measurement variation, a range must be estab-
lished. We chose an absolute cutoff of 10 mm for the
purposes of this report but continue to collect data with the
ure or device are listed
Description
spital ventricular tachycardia
l
perforation of stomach and gallbladder after intentional coverage
c artery
bolization to mesenteric, renal and lower extremity, paraplegia
n embolic CVA, recovered most of neurologic function, died at
tation facility
cm AAA scheduled for repair 1 month after thoracic repair
onate-use treatment for bleeding AEF 8 years after an
leted elephant trunk procedure
bolization to mesenteric and renal vasculature
g from a procedure-induced thalamic infarct in a rehabilitation
d a pancreatic fistula after a mesenteric bypass procedure
ng the endograft. Sepsis developed from the fistula 3 months
nt graft implantation
-dependent patient before endograft implant, pneumonia
ed remote from procedure.
I 1 day after a proximal extension graft placement
t preceded by open AAA repair and visceral vessel bypass. Fistula
n autopsy to be remote from endograft and bypass procedure in
al segment of aneurysm
re;CVA, cerebrovascular accident;AAA, abdominal aortic aneurysm; AEF,
xsanguination was likely from continued intercostal perfusion.
tprocedure while in pulmonary rehabilitation setting, possibly related toroced
of ho
ospita
emic
celia
al em
red a
habili
wn 7-
passi
comp
al em
verin
cility
elope
ecedi
ter ste
tilator
velop
red M
ograf
ted o
e dist
n failu
The ehope of further defining when any observed migration may
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the migration rate in this series was low, despite most
patients having 1 year of follow-up. The values reported
unquestioningly underpredict the ultimate migration inci-
dence. We did process all available imaging studies with
meticulous analyses using 3D reconstruction and measure-
ment techniques and used the left common carotid and
celiac arteries as reference vessels.
It is more difficult to define a region of normal aorta
surrounding a thoracic aorta than in the setting of infrare-
nal repair. Complete thoracic aortic coverage was not de-
sirable for relatively focal aneurysms, and thus a calculated
risk involving moderate coverage of the thoracic aorta in an
effort to minimize the risk of paraplegia was undertaken. A
conservative coverage policy in these patients would predict
a potentially higher incidence of secondary interventions as
a result of further degeneration of the proximal or distal
thoracic aortic. This was not observed in this series; how-
ever, the follow-up duration is not likely long enough for
the detection of late fixation site dilation.
Although this series was prospective with defined inclu-
sion criteria, a degree of judgement was used during the
patient selection process. Other devices (the W.L. Gore
TAG and Medtronic Talent) were intermittently available
during the patient accrual process. In general, patients were
preferentially enrolled in prospective multicenter trials if
they qualified for such. They were considered for this
protocol if they did not meet multicenter trial inclusion
criteria or no other trials were enrolling. Exceptions to this
were made when, in the treating physicians judgement, one
device would be more preferential than another given the
anatomic situation and various device limitations. To add
perspective to this issue, approximately 25 patients were
enrolled in multicenter trials compared with the 100 pa-
tients in this study. Clearly, these factors preclude general-
ized, concurrent, device comparison studies and likely af-
fect the results of each trial.
This device was associated with a high degree of technical
success in a very complex patient population, which attests to
its deliverability in both straight-forward and challenging an-
atomic situations. A comparitvely high rate of procedure-
related mortality in contrast with the endovascular treatment
of infrarenal aneurysms was noted; however, this correlates
closely with the extreme patient population being treated.
Endoleaks were uncommon (particularly type II endoleaks)
and when present, frequently required treatment with the
extension of the proximal or distal aspect of the graft. Favor-able behavior of the aneurysm sac was noted in most patients
through 24 months of follow-up, with only one patient ex-
hibiting growth attributed to a type I endoleak. The sac
behavior parallels that of theZenith infrarenal device, and thus
any patient exhibiting aneurysmal growth should be carefully
evaluated.Migrationwas uncommon in the presence of active
(barb) fixation systems in the absence of an uncovered proxi-
mal stent, and no device integrity issues have been noted.
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